Darnisha Grant Harrison is the President & CEO of Ennaid Therapeutics, a development-stage biopharmaceutical company. As the company’s Head, she is responsible for guiding the company to its intention of being first-to-market with the world’s first therapeutic cure for two of the most notorious mosquito-borne diseases in the world, Zika virus and dengue virus. There are a total of eleven drugs in the company’s pipeline.
Once a Microbiologist and Chemist, Darnisha is now a nationally recognized pharmaceutical entrepreneur by Newsweek Magazine and has greater than twenty-four years’ experience in the Life Sciences.
Prior to founding Ennaid Therapeutics, she spent three years as a scientist, most notably at Amgen and the University of Georgia, and sixteen years in Business Development/Licensing as a Director in various companies within the pharmaceutical research & development industry.
She is an accomplished negotiator and deal-maker in identifying, negotiating and closing drug development deals and strategic collaborations. Darnisha is accomplished in technology acquisition and licensing, strategic business development, business planning and brisk, successful execution of such plans. A member of the American Association for the Advancement of Science, the New York Academy of Sciences, The World Chamber of Commerce and Women In BIO, Darnisha received a B.S. in Microbiology and Minor in Chemistry from LSU.
William J. Brock is the Principal of Brock Scientific Consulting, LLC. He has about 30 years of experience as a toxicologist, manager and consultant for research and development in the pharmaceutical, consumer product, food, medical device and chemical industries. Experienced in occupational and industrial toxicology; nonclinical safety program study design, conduct, interpretation and reporting; evaluating clinical and product safety data; in training and managing staff; dealing with a wide range of U.S. and foreign regulatory bodies, commercial concerns, and contract research organizations; labeling and other regulatory compliance issues; writing reports, regulatory and toxicology position papers; presentations to regulatory authorities; risk and safety assessments and litigation support. He attended University of Kentucky in Lexington, Kentucky (1980-1983) and earned a Ph.D. in Toxicology.
Michael has 20 years experience in the Medical Diagnostic and Pharmaceutical industries. Qualifications include a broad range of experiences in pharmaceutical sales, sales training, representative development, sales management as well as medical diagnostic distribution. Having served as a Pharmaceutical Sales Trainer / Manager, Michael has assisted in the commercial launch of several blockbuster pharmaceutical products. He brings the experience of a stellar award winning sales track record having won multiple sales awards in the pharmaceutical and medical diagnostic industries. Michael received his Bachelor of Science degree in Chemistry from Tennessee State University and is currently completing his MBA in conjunction with a Six Sigma Lean Green Belt certification from Indiana University, School of Business and Economics Northwest Campus.
Chief Finance Officer
Mark Shipley is a finance, accounting and IT professional with over 25 years’ experience. Over the course of his career he has focused on General Ledger accounting, financial planning and analysis, best practices, financial systems design and analysis, advanced accounting and complex financial modeling.
He is considered a leader in Financial Analysis, Financial Modeling and Business Intelligence (BI). Mark has a BSBA in accounting and a Master of Accountancy from the University of Tennessee.
Chief Scientific Officer
Dr. Michael is a co-inventor of Ennaid Therapeutics’ dengue peptide technology. His previous accomplishments include major discoveries on HIV protease inhibitor resistance and the origin of HIV-1 from chimpanzees. His current research interests are directed towards the development of anti-virals and vaccines against dengue virus. He serves on the editorial boards of Virology Journal and PLOS Neglected Tropical Diseases. Dr. Michael received a Ph.D. in Chemistry from the Johns Hopkins University.
VP of Pharmaceutical Sciences Consultant/CMC Development, & Scientific Advisory Board
With greater than thirty years of experience in the pharmaceutical and related industries, Dr. Moreton is currently the V.P. of Pharmaceutical Sciences at FinnBrit Consulting. Dr. Moreton spent the bulk of his career at Penwest Pharmaceuticals and Idenix Pharmaceuticals, where he served as VP of Pharmaceutical Sciences. His extensive expertise in the pharmaceutical industry is in preformulation, formulation and process design and development, scale-up and clinical manufacture, technical transfer to commercial manufacture, process validation, analytical method development and validation, quality assurance, excipients, GMPs for excipients, pharmaceutical finished products, nutritional products and APIs, CMC regulatory documentation, contract manufacturing and development and packaging. Dr. Moreton’s additional specialties include pharmaceutical product development, clinical manufacture, project coordination and mangement, technical transfer, CGMP and scale-up. He received a Ph.D. in Pharmaceutics from Cardiff University/Prifysgol Caerdydd.
Scientific Advisory Board
GARY H.S. STRAUSS is a dedicated medical research scientist with doctoral and post-doctoral training in medical microbiology, immunology, medical genomics, and toxicology. A principal investigator in US and British government laboratories, as well as a research professor at a prominent US medical school, and collaborator with several biotechnology companies, he spent over twenty years conducting original research while also fulfilling requisite mentoring and administrative responsibilities. Lab work took precedence in those years as he developed new methods for measuring drug resistance and other genetically-induced and -determined responses to environmental mutagens/ carcinogens including, in many instances, medical therapies then undergoing ICH- and FDA-supervised clinical trials. In his laboratory years, he also introduced novel methods for use in stem- and differentiated cell cryopreservation and assessing immunocompetency, but he is best known as co-inventor of the seminal technology for detecting, enumerating, and monitoring mutant frequencies among somatic cells arising in-vivo and induced in-vitro. Gary received his PhD in Medical Microbiology from the U. Vermont College of Medicine, Burlington, VT and a DPhil in Genetic Toxicology from U. Sussex Medical Research Council, Brighton, UK.
Dr. Myeni has a background in both business and medicine. In addition to having a history in sales and logistics, she is an ophthalmologist who has completed advanced specialty training in both the medical and surgical management of glaucoma. Dr. Myeni received a Doctor of Medicine degree from the Medical College of Georgia. Thereafter, she acquired a Masters in Public Health from Harvard University, with a concentration in Health Management and she received an undergraduate degree from the Amherst College. She completed her residency training in ophthalmology at Howard University Hospital, after which she acquired a fellowship in glaucoma at Wills Eye Hospital in Philadelphia, PA. Dr. Myeni is currently a practicing Ophthalmologist in Washington, D.C.
Sr. Process Engineer, Manager of Technical & Scientific Affairs, & Scientific Advisory Board
With twenty one years of experience in the pharma industry Romeo is a stellar scientist and has worked in big pharma and small start-up pharma companies. He has held positions at Abbott/now Abbvie, Sciele Pharma & Wockhardt. His expertise is in basic chemistry, tech transfer, process development and optimization, scale-up/down and validation. He has many years of experience managing outsourced development projects. Romeo has a Masters in Chemistry, a Masters in Chemical Engineering and a B.S. in Chemistry from the University of Illinois, Chicago.
Chief Operating Officer
William Howe, COO, is responsible for guiding the strategic direction and growth of Ennaid. He is also the Founder & CEO of VehWare. William has over twenty years of successful management and leadership experience with a reputation for meeting the most challenging organizational goals and objectives. His recent work includes development of eye tracking technologies that will enable persons with disabilities to use their eyes to control a wheelchair. Another aspect is detection and tracking of brain function affected by concussions, chemical impairment and diseases such as Zika and Dengue viruses.
Bill is a retired U.S. Navy Photographer with tours of duty in Guam, Antarctica, China Lake California and Kauai Hawaii. He was also a Naval Aircrewman with over 2000 hours if flight time in various military aircraft. He was the Optical Program Manager at Pacific Missile Range Facility, where he spearheaded development of electro-optical systems. He developed proposals of techniques and systems in support of various Defense Department organizations, including Strategic Defense Initiative Organization (SDIO commonly referred to as Star Wars). As a business owner of Howe Photography, he operated the largest commercial photo studio and processing facility in Northern Indiana.
He received Magna Cum Laude honor at Bethel College, where he completed a Bachelor of Science in Organizational Management. His education also includes Quality Control of Processes at Rochester Institute of Technology. He has received numerous awards and citations for developing solutions supporting operations in Antarctica, California, Hawaii and other locations.
Chief Strategy Officer
Janet is Chief Strategy Officer to Ennaid. She has over 25 years of entrepreneurship; developing corporate strategy for a wide variety of biopharmaceutical clients; building teams and strategies to launch new drugs; and expand existing international markets.
She is purposeful and sets extraordinarily high standards of quality for herself and the teams with whom she aligns.
Janet received her Bachelor’s degrees in both Biology and Chemistry from Mercer University and most recently owns the VonKohn Family of Companies to provide services across the biopharmaceutical spectrum.
Janet has been married to her husband, Lon since 1992, has two grown children, and one beautiful grand princess. She and her husband make their home in Nashville, TN.